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ABSTRACT
Background and Objectives: Renal insufficiency (RI) has been reported to be associated with unfavorable clinical out-
comes in patients undergoing percutaneous coronary interventions (PCI). However, little data is available regarding the im-
pact of moderate to severe RI on clinical outcomes in patients with acute myocardial infarction (AMI) undergoing PCI. 
Subjects and Methods: Between March 2003 and July 2007, 878 patients with AMI who underwent PCI were enrolled. 
Based on estimated glomerular filtration rate (eGFR) using the Modification of Diet in Renal Disease (MDRD) equation, pa-
tients were divided into two groups: eGFR <60 mL/min·m
2 (moderate to severe RI, group A) and eGFR ≥60 mL/min·m
2 (nor-
mal to mild RI, group B). The primary endpoint was all-cause mortality at 1-year after successful PCI. The secondary endpoints 
were non-fatal myocardial infarction (MI), target lesion revascularization (TLR), target vessel revascularization (TVR), stent 
thrombosis (ST) and major adverse cardiac events (MACE) at 1-year. Results: In group A, patients were more often male and 
older, with diabetes and hypertension. Compared to patients in group B, group A showed significantly higher incidences of all-
cause mortality, cardiac mortality, non-fatal MI and MACE. The needs of TLR and TVR, and the incidence of ST were not sig-
nificantly different between the two groups. Independent predictors of 1-year mortality were eGFR <60 mL/min·m
2, male 
gender, older age and a lower left ventricular ejection fraction. Conclusion: In patients with AMI, moderate to severe RI 
was associated with mortality and MACE at 1-year after successful PCI. In addition, eGFR <60 mL/min·m
2 was a strong in-
dependent predictor of 1-year mortality. (Korean Circ J 2011;41:308-312)
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Introduction
Renal insufficiency (RI) has been reported to be one of the 
most important risk factors of mortality in patients who un-
dergo percutaneous coronary intervention (PCI).
1) It is also kn-
own to be associated with poor cardiovascular outcomes in 
patients with acute myocardial infarction (AMI).
2-5) Little is 
known, though, about the impact of moderate to severe RI on 
the long-term clinical outcome in patients with AMI who un-
dergo PCI. In fact, moderate to severe RI has been excluded 
in most large clinical trials because of both the high rate of co-
morbidity and the failure to use adequate medications such 
as β-blockers and acetylcholine esterase inhibitor, due to the 
hemodynamic instability during the procedure and admiss-
ion period.
6) 
A Recent study showed that estimated glomerular filtra-
tion rate (eGFR) <60 mL/min·m
2 was associated with unfavor-
able clinical outcomes in patients undergoing PCI.
1)7) The RI 
with eGFR <60 mL/min·m
2 may be a pre-clinical sign of end-
stage renal disease which has been documented to have a poor 
clinical outcome in patients with AMI who undergo PCI.
8) Th-
erefore, the purpose of this study was to evaluate the impact 
of moderate to severe RI (eGFR <60 mL/min·m
2) on the clini-
ca outcomes in patients with AMI who undergo PCI. Jihyun Son, et al.   309
Subjects and Methods
Study population
Between March 2003 and July 2007, 878 patients with AMI 
(within 72 hours) who underwent PCI were consecutively 
enrolled. Patients with ST-segment elevation MI (STEMI) 
underwent primary PCI, and patients with non-ST segment 
elevation MI (NSTEMI) underwent emergent or elective PCI. 
Patient age was limited to 18 to 80 years. Based on eGFR, us-
ing the Modification of Diet in Renal disease (MDRD) equ-
ation, patients were divided into two groups: group A, with 
eGFR <60 mL/min·m
2 (moderate to severe RI; n=255) and 
group B, with eGFR ≥60 mL/min·m
2 (normal to mild RI; 
n=623). Dermographic, clinical, and angiographic charac-
teristics, as well as follow-up data were collected in both gr-
oups. Medical records were reviewed and family members 
were interviewed, when necessary, to determine cause of death.
Exclusion criteria were as follows: 1) thrombolysis before 
PCI, 2) cardiogenic shock, 3) acute renal failure before PCI, 
4) renal transplantation before PCI, 5) under dialysis at the 
time of presentation. 
Definitions
Renal function was estimated according to the calculated 
creatinine clearance which was derived from eGFR, which in 
turn was estimated from the concentration of serum creati-
nine at admission, before PCI, by using MDRD equation : 
eGFR (mL/min per 1.73 m
2 of body surface)=186×{serum 
creatinine (mg/dL)}
-1.154×{age (in years)}
-0.203 (for women, 
the value was multiplied by 0.742). This equation is from the 
2002 Kidney Disease Outcomes Quality Initiative (KDOQI) 
guideline,
9) and has a close correlation with measured GFR 
(correlation coefficient 90.3). 
Myocardial infarction was defined by the presence of two 
of three criteria: chest pain persisting at least 20 minutes, 
electrocardiographic changes and cardiac enzyme level in-
creased to at least twice the upper limit of the normal range.
10) 
The number of diseased coronary arteries was defined by th-
ose major coronary arteries with luminal diameter stenosis 
greater than or equal to 70%. As well, patients with stenosis 
of the left main coronary artery that was more than or equal 
to 50% were considered as having two-vessel disease. Success-
ful PCI was achieved if procedural success was obtained, de-
fined as no remaining vessel stenosis more than or equal to 
30%, without in-hospital major adverse cardiac events (MACE). 
Mortality from cardiac disease, non-fatal MI, target lesion 
revascularization (TLR), target vessel revascularization (TVR) 
and stent thrombosis (ST) were included in MACE. Cardiac 
death was considered to have occurred if death was associated 
with documented MI or other cardiac causes, such as conges-
tive heart failure and arrhythmia. ST was recorded according 
to the definition of the American Research Consortium.
11) 
Statistical analysis
The relationship between presence of certain characteris-
tics or risk factor and clinical outcome was evaluated by bi-
nary comparison with the Pearson chi-square test and pre-
sented as counts and percentages. The associations between 
continuous variables were evaluated using ANOVA test and 
were presented as their means and standard deviations. Af-
ter testing all variables with univariate analysis, those with p-
value less than 0.1 and with possible risk factors document-
ed in previous studies were entered in a multivariate Cox pro-
portional hazards regression model, in order to evaluate inde-
pendent predictive power for mortality and MACE. The ev-
ent-free survival curves were constructed using the Kaplan-
Meier method. P≤0.05 were considered significant. The 
Statistical Package for the Social Sciences (SPSS) software pa-
ckage (version 15.0 for windows; SPSS Inc., Chicago, IL, USA) 
was used for statistical analysis.
Results
Patient clinical characteristics
The baseline demographics are shown in Table 1. The study 
population consisted of 878 patients including 385 with 
STEMI and 493 patients with NSTEMI. Patients tended to be 
older and male, diabetic and hypertensive in group A (p< 
0.001 for all comparisons). Left ventricular ejection fraction 
(LVEF) and incidence of STEMI were not significantly dif-
ferent between the two groups. 
Angiographic and procedural results
Angiographic results are demonstrated in Table 2. The in-
cidence of multiple vessel disease was higher in group A. Dise-
ased vessel, stent length, stent size, initial diameter of stenosis 
and presence of chronic total occlusion were not different be-
Table 1. Baseline characteristics
Characteristics 
eGFR ≥60
(n=623) 
eGFR <60
(n=255) 
p
Mean eGFR (mL/min·m
2)  80.7±14.3  48.1±11.4  <0.001 
Age (years) 59.5±11.4  67.8±8.80 <0.001 
Male, n (%)  482 (77.4)  130 (51.0)  <0.001 
Diabetes, n (%)  104 (16.7)  080 (31.4)  <0.001 
Hypertension, n (%)  214 (34.3)  141 (55.3)  <0.001 
STEMI, n (%)  275 (44.1)  110 (43.1)  NS 
Primary PCI, n (%) 179 (28.7) 093 (36.5) 0.030
BSA (m
2) 1.67±0.33  1.63±0.25  NS 
Serum creatinine (mg/dL)  0.97±0.16  1.51±0.89  <0.001 
Mean LVEF, n (%) 48.4±9.8  47.4±10.3  NS 
eGFR: estimated glomerular filtration rate, STEMI: ST-elevation 
myocardial infarction, PCI: percutaneous coronary intervention, 
BSA: body surface area, LVEF: left ventricular ejection fraction, NS: 
no significance310   Renal Insufficiency in Acute Myocardial Infarction
tween two groups.
Clinical outcome
Mean follow-up period was 381.0±34.9 days. The 1-year 
follow-up results are shown in Table 3. The incidence of all-
cause mortality was 10.2% in group A and 3.2% in group B 
(p<0.001), and cardiac mortality rate was 5.9% in group A 
and 1.9% in group B (p=0.004). The incidence of non-fatal 
MI was 3.9% in group A and 0.8% in group B (p=0.003). Th-
erefore the incidence of MACE was significantly higher in 
group A than it was in group B (16.1% vs. 6.1%, p<0.001). 
However the needs of TLR, TVR and ST were not signific-
antly different between two groups. Risk factors of 1-year mor-
tality were shown in Table 4. Multivariate analysis identified 
that eGFR <60 mL/min·m
2, male gender, older age and lower 
LVEF were independent predictors of 1-year mortality (Ta-
ble 5). Hazard ratios for 1-year mortality of eGFR <60 mL/ 
min·m
2, male gender, age and LVEF were 2.02 {95% confi-
dence interval (CI), 1.05-3.87; p=0.033}, 2.52 (95% CI, 1.19-
5.32; p=0.015), 1.06 (95% CI, 1.03-1.10; p<0.001) and 0.94 
Table 2. Angiographic and procedural characteristics
Characteristics 
eGFR ≥60
(n=623) 
eGFR <60
(n=255) 
p
Multiple vessel disease, n (%)  272 (43.7)  137 (53.7)  0.007 
LM/LAD lesion, n (%)  293 (47.0)  106 (41.6)  NS 
CTO, n (%)  04 (0.6)  01 (0.4)  NS 
Total stent length (mm)  036.41±198.04  29.66±15.13  NS 
Stent size (mm)  3.24±0.42  3.22±0.38  NS 
Initial DS, n (%)  88.06±10.05  89.18±9.670 NS 
Initial MLD (mm)  0.36±0.32  0.32±0.29  NS 
Final DS, n (%)  8.87±3.35  8.72±3.92  NS 
Final MLD (mm)  2.97±0.44  2.95±0.42  NS 
Fluorotime (minute)  15.0±5.30  14.6±5.6 0 NS 
Dose of dye (mL)  258.84±108.96 261.06±101.56  NS 
eGFR: estimated glomerular filtration rate, LM: left main, LAD: left 
anterior descending, CTO: chronic total occlusion, DS: diameter ste-
nosis, MLD: minimum lumen diameter, NS: no significance
Table 3. Clinical outcomes according to severity of renal insuf-
ficiency, at 1-year after PCI
eGFR ≥60 
(n=623) 
eGFR <60
(n=255) 
p
All-cause death, n (%)  20 (3.2)  26 (10.2)  <0.001 
Cardiac death, n (%)  12 (1.9)  15 (5.9)0 0.004 
Myocardial infarction, n (%)  05 (0.8)  10 (3.9)0 0.003 
Target lesion revascularization, 
  n (%) 
11 (1.8)  7 (2.7)  NS 
Target vessel revascularization, 
  n (%) 
16 (2.6)  1 (3.5)  NS 
Stent thrombosis, n (%)  05 (0.8)  5 (2.0)  NS 
MACE, n (%)  38 (6.1)  41 (16.1)  <0.001 
PCI: percutaneous coronary intervention, eGFR: estimated glo-
merular filtration rate, MACE: major cardiac adverse events, NS: 
no significance
Table 4. Risk factors of 1-year mortality on univariate analysis
Characteristics
1-year mortality 
p
(-) (n=832) (+) (n=46)
Age (yeras) 61.51±11.28  69.83±10.29  <0.001 
Mean LVEF, n (%) 48.41±9.920 43.19±10.50  0.001 
eGFR <60 mL/min∙m
2, 
  n (%)
229 (27.5)  26 (56.5)  <0.001 
Female, n (%) 252 (30.3)  14 (30.4)  NS 
Mean BSA (m
2) 1.67±0.29  1.54±0.39  0.010 
STEMI, n (%) 363 (43.6)  22 (47.8) NS 
Primary PCI, n (%) 249 (29.9) 23 (50.0) 0.008
Hypertension, n (%) 337 (40.5)  18 (39.1)  NS 
Diabetes, n (%) 173 (20.8) 11 (23.9) NS
Hyperlipidemia, n (%) 137 (16.5)  2 (4.3)  0.023 
Multiple vessel disease, 
   n (%)
382 (45.9)  27 (58.7)  NS 
LM/LAD lesion, n (%) 373 (44.8)  26 (56.5)  NS 
LVEF: left ventricular ejection fraction, eGFR: estimated glomeru-
lar filtration rate, BSA: body surface area, STEMI: ST-segment elev-
ation myocardial infarction, PCI: percutaneous coronary interven-
tion, LM: left main, LAD: left anterior descending, NS: no signific-
ance
Table 5. Multiple logistic predictors of 1-year mortality
Hazard ratio  95% CI  p
Age  1.07  1.03-1.10  <0.001 
Male  2.52  1.19-5.32  0.015 
Diabetes  1.06  0.52-1.90  NS 
Hypertension  0.99  0.52-1.90  NS 
Hyperlipidemia  0.38  0.09-1.59  NS 
STEMI  1.40  0.76-2.59  NS 
Primary PCI 1.56 0.80-3.02 NS
Multiple vessel disease  1.02  0.54-1.92  NS 
Ejection fraction  0.94  0.90-0.98  0.004 
eGFR <60 mL/min∙m
2 2.02  1.05-3.87  0.033 
CI: confidence interval, BSA: body surface area, STEMI: ST-segment 
elevation myocardial infarction, eGFR: estimated glomerular filtra-
tion rate, NS: no significance
Table 6. Prognostic value of moderate to severe renal insuffici-
ency for 1-year mortality*
Variable Hazard ratio (95% CI) p
No adjustment 3.28 (1.83-5.88) <0.001
Model 1 2.15 (1.17-3.94) 0.013
Model 2 2.41 (1.31-4.44) 0.005
Model 3 2.07 (1.09-3.91) 0.025
Candidates for adjustment: model 1 was adjusted for age; model 2 
was adjusted for age and sex; model 3 was adjusted for age, sex and 
left ventricular ejection fraction. *Cox proportional hazards mod-
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(95% CI, 0.90-0.98; p=0.004), respectively. Hazard ratio for 
1-year mortality of eGFR <60 mL/min·m
2 with no adjustment 
was 3.28 (95% CI, 1.83-5.88; p<0.001), and there was signifi-
cant predictive value after adjustment for age, sex, and LVEF 
(Table 6).
The occurrence of death during follow-up is depicted in Fig. 1. 
Kaplan-Meier curves revealed that patients in group A had a 
higher cumulative rate of death after 1-year follow-up (p< 
0.001).
Discussion
This study demonstrated that patients with moderate to 
severe RI have a significantly higher incidence of all-cause 
mortality, cardiac mortality, non-fatal MI, and MACE. Furth-
ermore, moderate to severe RI, being male, a higher age and 
LVEF were independent predictors of 1-year mortality after 
successful PCI in patients with AMI.
Atherosclerotic risk factors seem to be associated with re-
nal function in the general population. One previous study 
suggested that age, diabetes and hypertension were related 
to RI because of the involutional process or atherosclerotic 
changes.
12) However, there has been controversy in defining 
gender as a risk factor of RI. Hsu et al.
12) and Plantinga et al.
13) 
demonstrated that RI was more prevalent in males than in 
females, and in another study, males had an increased risk of 
RI.
1) Increased incidence atherosclerosis is a possible cause of 
the increased risk of RI in males. 
Isolated measurement of plasma creatinine has been com-
monly used for assessing renal function. However, Levey et 
al.
14) reported the inaccuracy of plasma creatinine for eGFR 
because plasma creatinine could change easily with the pa-
tient’s circumstances, such as age and gender. The authors 
suggested MDRD equation as the most reliable method to 
estimate GFR, as it takes into consideration both age and 
gender when estimating GFR. In this study, MDRD equation 
by KDOQI was used for the estimation of GFR, translating 
into a more reliable evaluation of real kidney function.
The possible explanations of the unfavorable clinical out-
comes in AMI patients with moderate to severe RI are that 
RI is frequently associated with congestive heart failure and 
diabetes mellitus which are known to be associated with poor 
clinical outcomes.
5) Moreover, RI itself has a hazardous effect 
on the patient with AMI, partly due to raised oxidative stress 
and inflammation,
15) alteration of lipid metabolism,
16)17) cal-
cium-phosphate homeostasis, elevated homocystein,
18)19) co-
agulation and endothelial dysfunction.
20)21) Numerous studies 
have shown that advanced age, female gender, congestive he-
art failure, diabetes and RI were important predictors of mor-
tality in patients with end-stage renal disease and AMI,
22)24) 
which is, except for diabetes, in line with our study. In this stu-
dy, low-density lipoprotein (LDL) levels in patients with dia-
betes were significantly lower than those of patients without 
diabetes (121.7±36.6 vs. 129.6±39.1, p=0.014), suggesting 
that early survelliance of dyslipidemia and vigorous treat-
ment with lipid-lowering agent may affect this result.
Moderate to severe RI was associated with increase of 
1-year mortality and MACE in patients with AMI undergo-
ing PCI. Furthermore, eGFR <60 mL/min·m
2 using MDRD 
equation by KDOQI was the strongest predictor of 1-year 
mortality. Close surveillance, intense medical treatment and 
lifestyle modification should be required in this patient subset. 
This study has several limitations. First, the number of pa-
tient is relatively small and, being a retrospective study with 
a single center experience, it may have a source of selection 
bias. Also, because of the limited number of patients in each 
group, it was underpowered to detect a statistical significance. 
Second, a more stratified RI, such as normal, mild, moderate 
and severe, could provide a more precise impact of RI on clini-
cal outcomes in this patient subset. Third, patients receiving 
dialysis were not included in this study. This may have some 
limitations for evaluation of the real impact of severe RI on 
patients with AMI undergoing PCI. Fourth, there was no con-
sideration of contrast induced nephropathy. Therefore, a ran-
domized study which is stratified with the grade of RI and wh-
ich has a larger number of patients will have more value and 
could be useful to do the future. 
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